<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307511</url>
  </required_header>
  <id_info>
    <org_study_id>2020PYN</org_study_id>
    <nct_id>NCT04307511</nct_id>
  </id_info>
  <brief_title>A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients</brief_title>
  <acronym>TIGER-diabetes</acronym>
  <official_title>A Randomized Controlled sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg)&#xD;
      had similar anti-platelets function compared with the standard dose ticagrelor in acute&#xD;
      coronary syndrome patients with diabetes. Totally 40 ACS patients with diabetes will be&#xD;
      divided into 2 groups randomly after PCI for one month. Group 1 will be treated with&#xD;
      ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group; Group2 will&#xD;
      be treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard&#xD;
      DAPT treatment. The platelets function will be tested in VASP and TEG methods at 1 and 2&#xD;
      months after PCI as the primary endpoints.The clinical events will be observed 12 months&#xD;
      after PCI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of PRI detected by VASP</measure>
    <time_frame>changes of PRI from baseline (1 months after index PCI) to 2 months after index PCI</time_frame>
    <description>platelet reactivity index (PRI) detected by VASP (Vasodilator Stimulated Phosphoprotein) Phosphoprotein)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of Maximum Amplitude (MA) detected by TEG</measure>
    <time_frame>changes of MA from baseline (1 months after index PCI) to 2 months after index PCI</time_frame>
    <description>Maximum Amplitude (MA) detected by TEG(Thromboelastography)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Coronary Syndrome Patients With Diabetes After PCI</condition>
  <arm_group>
    <arm_group_label>low dose DAPT therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose DAPT therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy</description>
    <arm_group_label>low dose DAPT therapy</arm_group_label>
    <arm_group_label>standard dose DAPT therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin</description>
    <arm_group_label>low dose DAPT therapy</arm_group_label>
    <arm_group_label>standard dose DAPT therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years of age and less than 90 years old&#xD;
&#xD;
          2. Patients should have undergone successful percutaneous coronary intervention with&#xD;
             drug-eluting stent for acute coronary syndrome with diabetes mellitus.&#xD;
&#xD;
          3. Subject understand the study requirements and the treatment procedures and&#xD;
&#xD;
          4. provided informed consent before the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study&#xD;
&#xD;
          2. Active bleeding&#xD;
&#xD;
          3. Known hypersensitivity or contraindication to study medications&#xD;
&#xD;
          4. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study&#xD;
&#xD;
          5. Non-cardiac co-morbid conditions are present with life expectancy &lt;2 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          6. Subjects with Cerebral hemorrhage history&#xD;
&#xD;
          7. Subjects with stroke history in half a year&#xD;
&#xD;
          8. subjects with active malignant tumor&#xD;
&#xD;
          9. subjects with whom oral anticoagulants are needed&#xD;
&#xD;
         10. Other conditions which the investigators think not applicable to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Hou, Doctor</last_name>
    <phone>13564868096</phone>
    <email>Dr_houlei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>shanghai Tongren hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200336</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Hou, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tong Ren Hospital</investigator_affiliation>
    <investigator_full_name>Hou Lei</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

